#033 $GSK’s Zantac Fallout Buried Cancer Risks and Billions in Liability

2025-06-15

GlaxoSmithKline $GSK allegedly hid a decades-old report showing its blockbuster drug Zantac could form a cancer-causing compound far beyond safe limits. Now, a securities class action says $GSK misled investors for years while lawsuits mounted. In this explosive episode of Bulls and Betrayal, Anna and Nate expose the cover-up, the internal science, and the $2.3B market hit. For pharma investors, legal junkies, and anyone who’s ever trusted a drug label. We’re not lawyers or accountants, so don’t take ...

GlaxoSmithKline $GSK allegedly hid a decades-old report showing its blockbuster drug Zantac could form a cancer-causing compound far beyond safe limits. Now, a securities class action says $GSK misled investors for years while lawsuits mounted. In this explosive episode of Bulls and Betrayal, Anna and Nate expose the cover-up, the internal science, and the $2.3B market hit. For pharma investors, legal junkies, and anyone who’s ever trusted a drug label.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.

🔬 Read the full case at ZLK.com | Follow @bullsandbetrayal

$GSK GlaxoSmithKline Zantac NDMA cancer lawsuit drug recall pharma scandal securities fraud shareholder class action FDA litigation whistleblower toxic risk disclosure Emma Walmsley Rule 10b5

Comments (3)